IL6 and COVID-19: Furthermore, DACH has a prodigious role in the management and treatment of patients with moderate or severe COVID-19 symptoms via targeting the early events during the replication cycle of SARS-CoV-2 (the main contributor to the COVID-19 pandemic) and preventing the induction of TNF-α, IL-6, and inflammatory mediators correlated with the cytokine storm of SARS-CoV-2 infectious disease [3–5].